Industry sponsored sessions
Discovering Healthcare Advancements: Sponsored Sessions Guide
- Esteemed professionals in the field will analyze recent trials and discoveries that will mold the future of clinical practice.
- Stay informed about the most recent data concerning HIV & co-infections progress and solutions.
12:00 – 13:00, room POLONEZ
Industry Sponsored Session – Virology Education
The Devil Wears GP120
Chair: Miłosz Parczewski (Poland)
|
Welcome by the Symposium Chair
|
12:00 - 12:05 |
|
The Role of GP120 in HIV Pathogenesis and Its Interactions with the Immune System
|
12:05 - 12:20 |
|
Clinical Data from the GP120 Inhibitor Temsavir and Its Potential Relevance to Immune Reconstitution and HIV
|
12:20 - 12:35 |
|
Future Study of GP120 Inhibitors as Potential Immunomodulators in Clinical Care
|
12:35 - 12:50 |
| Discussion - Live Q&A |
12:50 - 13:00 |
|
Closure of the Symposium
|
13:00 |
15:00 – 16:30, room POLONEZ
Industry Sponsored Session – PeerVoice
Individualising ART as We Travel Through Time: Decisions Along a Life’s Journey
Chair: Sharon Walmsley (Canada)
|
Welcome and Introduction
|
15:00 - 15:05 |
|
Living a Full Live with HIV
|
15:05 – 15:12 |
|
Initiating ART at Diagnosis: When and With What?
|
15:12 – 15:29 |
|
ART and Pregnancy: How Do We Ensure ‘Safe’ Management of Mother and Baby?
|
15:29 – 15:46 |
|
When Viral Suppression is Achieved: What Now?
|
15:46 – 16:03 |
|
Managing Age-Related Changes Alongside Maintaining Viral Suppression: Menopause and More!
|
16:03 - 16:20 |
| "Ask the Faculty” and Take-Home Messages | 16:20 - 16:30 |
16:30 - 17:30, room MAZUREK
Industry Sponsored Session – ViiV Healthcare
The Power of Voice: Focusing on Health-Related Quality of Life in People Living with HIV
Chair: Justyna Kowalska (Poland), Christine Katlama (France)
|
Welcome and introduction
|
16:30 – 16:32 |
|
HIV + healthy: What does it really mean?
|
16:32 - 16:47 |
|
Individual perspectives on individualising HIV care
|
16:47 – 17:12 |
|
Panel discussion and Q&A |
17:12 – 17:27 |
|
Conclusions and close
|
17:27 – 17:30 |
This ViiV Healthcare-sponsored promotional symposium is intended for prescribing healthcare professionals only. According to local regulations in Poland, this symposium should not be attended by non-prescribing healthcare professionals. Date of approval: September 2023 NP-GBL-HVX-WCNT-230033
16:30 - 17:30, room ETIUDA
Industry Sponsored Session – Bavarian Nordic
What is the path to mpox elimination and control?
Chair: Magdalena Ankiersztejn-Bartczak (Poland)
|
Introduction by symposium chair
|
16:30 - 16:40 |
|
Global strategic framework for mpox elimination – integration with HIV & STI programs
|
16:40 - 16:55 |
|
Mobilization & Advocacy: The Queer Community & The Mpox Response
|
16:55 - 17:10 |
| Q&A | 17:10 - 17:30 |
12:15 - 13:45, room POLONEZ
Industry Sponsored Session – ViiV Healthcare
The power of choice: Taking an individualised approach to HIV care
Chair: Nneka Nwokolo (UK), Georg Behrens (Germany)
|
Welcome and introduction to individualised care
|
12:15 – 12:30 |
|
The power of choice: Recent evidence and experience of two-drug regimens
|
12:30 – 13:05 |
|
The power of choice: Unlocking long-acting treatment options in HIV care
|
13:05 – 13:40 |
|
Conclusions and close
|
13:40 – 13:45 |
This ViiV Healthcare-sponsored promotional symposium is intended for prescribing healthcare professionals only. According to local regulations in Poland, this symposium should not be attended by non-prescribing healthcare professionals. Date of approval: September 2023 PM-GBL-HVX-BRFS-230003
16:00 - 17:00, room POLONEZ
Industry Sponsored Session – MSD
Current and key topics in HIV management - A collaborative discussion
Chair: Miłosz Parczewski (Poland)
|
Welcome and introduction
|
16:00 – 16:10 |
|
Should cardiometabolic considerations play a role in HIV treatment decision?
|
16:10 – 16:25 |
|
Individualization of treatment: Does one size fit all?
|
16:25 – 16:40 |
|
When would a next-generation NNRTI be the best option?
|
16:40 – 16:55 |
|
Closing remarks
|
16:55 – 17:00 |
This session is for prescribers only.
18:45 - 19:45, room POLONEZ
Industry Sponsored Session – Gilead
Treatment Selection for Long-Term Success: A Question of Empowerment
Chair: David Malebranche (USA)
|
Welcome and introduction
|
18:45 – 18:50 |
|
The shift to long-term success through treatment selection: How has the role of the people with HIV changed?
|
18:50 – 19:00 |
|
Sustained undetectable viral load: The starting point for treatment success
|
19:00 – 19:10 |
|
Long-term safety, tolerability and monitoring: What does this really mean?
|
19:10 – 19:20 |
| An optimised quality of life for all: The final goal for long-term success | 19:20 – 19:30 |
|
Audience Q&A
|
19:30 – 19:40 |
|
Conclusion and thanks |
19:40 – 19:45 |
This promotional meeting is organized by Gilead Sciences Europe Ltd and is intended for healthcare professionals only.
12:15 - 13:45, room POLONEZ
Industry Sponsored Session – Gilead
ART Resistance: A Question of Innovation.
Priorities for avoidance, understanding, and management
Chair: Sorana Segal-Maurer (USA)
|
Welcome and introduction Sorana Segal-Maurer (USA) |
12:15 - 12:25 |
|
Exploring the priorities for ensuring treatment success in diverse populations initiating ART
|
12:25 - 12:40 |
|
Stories of real-world success in adults with multi-drug resistant HIV-1 infection
|
12:40 – 13:05 |
|
Highlighting the progress made in ensuring virologic success in people with HIV switching ART
|
13:05 – 13:30 |
|
Audience Q&A
|
13:30 – 13:40 |
|
Conclusion and thanks
|
13:40 – 13:45 |
This promotional meeting is organized by Gilead Sciences Europe Ltd and is intended for healthcare professionals only.
17:30 - 18:30, room POLONEZ
Industry Sponsored Session - Janssen
Optimizing HIV outcomes in challenging scenarios in 2023: Is it now plain sailing?
Chair: Alan Winston (UK)
|
Welcome and Introduction
|
17:30 – 17:38 |
|
Challenging Scenario 1: Sailing rough seas
|
17:38 – 18:03 |
|
Challenging Scenario 2: In uncharted waters
|
18:03 – 18:28 |
|
Summary and close
|
18:28 – 18:30 |
